Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Oculis Labs
Switzerland
- Ownership
- Private
- Development stage
- Other
01
Overview
Oculis is developing a differentiated late-stage pipeline targeting major ophthalmology segments. The company focuses on neuro-ophthalmology and ophthalmic conditions with significant unmet medical needs, utilizing its proprietary OPTIREACH® technology platform
- Therapeutic areas
- NeurologyOphthalmology
- Modalities
- Small moleculeMonoclonal antibodyPeptoid small molecule
- Industry
- Biotech
02
Partnerships
LSP 7EarlybirdNovartis Venture FundPivotal bioVenture PartnersTekla Capital Management LLCVI Partners
Beyond the preview
Go deeper on Oculis Labs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oculis Labs.